title: Gabapentin prevents oxaliplatin-induced mechanical hyperalgesia in mice.
abstract: Oxaliplatin, a platinum-based chemotherapy drug, frequently causes acute and chronic peripheral neuropathies including mechanical hyperalgesia. These adverse effects hinder anticancer therapy with the drug. In this study, we examined several drugs that might prevent oxaliplatin-induced peripheral neuropathy. Single intraperitoneal (i.p.) injection of oxaliplatin (10 mg/kg) induced cold allodynia (acetone test) and mechanical hyperalgesia (von Frey test). Gabapentin, but not simvastatin and atorvastatin, prevented oxaliplatin-induced mechanical hyperalgesia without affecting cold allodynia. Moreover, oxaliplatin caused phosphorylation of cofilin protein in the spinal cord, which has been shown to be involved in the neuropathic hyperalgesia. This increased phosphorylation of cofilin was also attenuated by gabapentin treatment. These results suggest that gabapentin is useful for relieving oxaliplatin-induced mechanical hyperalgesia and that the pathogenic mechanisms of cold allodynia and mechanical hyperalgesia differ.
authors.affiliation: Laboratory of CNS Pharmacology, Graduate School of Pharmaceutical Sciences, Nagoya City University, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ohsawa
authors.forename: Saki
authors.initials: S
authors.lastname: Otake
authors.forename: Tomoyasu
authors.initials: T
authors.lastname: Murakami
authors.forename: Shohei
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Makino
authors.forename: Hideki
authors.initials: H
authors.lastname: Ono
mesh_terms: D051339:Actin Depolymerizing Factors / Q000378:metabolism; D000588:Amines / Q000008:administration & dosage* / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003080:Cold Temperature / Q000009:adverse effects; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage* / Q000494:pharmacology*; D000077206:Gabapentin; D006930:Hyperalgesia / Q000139:chemically induced* / Q000378:metabolism / Q000517:prevention & control*; D007274:Injections, Intraperitoneal; D008297:Male; D008815:Mice, Inbred Strains; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin; D010766:Phosphorylation / Q000187:drug effects; D013116:Spinal Cord / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage* / Q000494:pharmacology*
chemical_list: D051339:Actin Depolymerizing Factors; D000588:Amines; D000970:Antineoplastic Agents; D003509:Cyclohexanecarboxylic Acids; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin